Effect of NPC1L1 and HMGCR Genetic Variants With Premature Triple-Vessel Coronary Disease
Background: Both Niemann-Pick C1-like 1 (NPC1L1) and 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) play a key role on dyslipidaemia. We aim to evaluate whether NPC1L1 and HMGCR genetic variants are associated with susceptibility of premature triple-vessel disease (PTVD).Methods: Four singl...
Main Authors: | Xueyan Zhao, Jingjing Xu, Xiaofang Tang, Keyong Huang, Jiawen Li, Ru Liu, Lin Jiang, Yin Zhang, Dong Wang, Kai Sun, Bo Xu, Wei Zhao, Rutai Hui, Runlin Gao, Lei Song, Jinqing Yuan |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-12-01
|
Series: | Frontiers in Cardiovascular Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2021.704501/full |
Similar Items
-
Association of NPC1L1 and HMGCR gene polymorphisms with coronary artery calcification in patients with premature triple-vessel coronary disease
by: Yulong Li, et al.
Published: (2024-01-01) -
HMGCR gene polymorphism is associated with residual cholesterol risk in premature triple-vessel disease patients treated with moderate-intensity statins
by: Jiawen Li, et al.
Published: (2023-06-01) -
SIAH1 ubiquitination-modified HMGCR inhibits lung cancer progression and promotes drug sensitivity through cholesterol synthesis
by: Hongmei Yuan, et al.
Published: (2023-04-01) -
Therapeutic targets of hypercholesterolemia: HMGCR and LDLR
by: Ma S, et al.
Published: (2019-08-01) -
HMG-Coenzyme A Reductase as a Drug Target for the Prevention of Ankylosing Spondylitis
by: Zhenyu Zhong, et al.
Published: (2021-10-01)